Charlotte Firth

Medicine & Life Sciences

1. Clinical Trial Protocols 100%
2. Oropharyngeal Neoplasms 87%
3. Clinical Trials 85%
4. Rhabdomyosarcoma 78%
5. durvalumab 64%
6. Sarcoma 62%
7. Randomized Controlled Trials 44%
8. Data Management 43%
9. Pediatrics 42%
10. Psychological Handling 41%
11. Patient Participation 37%
12. Life Cycle Stages 35%
13. Workforce 31%
14. Radiotherapy 24%
15. Communication 24%
16. Learning 24%
17. Maintenance Chemotherapy 19%
18. Health Care Outcome Assessment 18%
19. Progression-Free Survival 17%
20. Cisplatin 16%
21. Survival 15%
22. Diffusion Magnetic Resonance Imaging 15%
23. Quality of Life 14%
24. Positron Emission Tomography Computed Tomography 14%
25. Fluorodeoxyglucose F18 13%
26. Drug Therapy 13%
27. Medical Futility 13%
28. Therapeutics 12%
29. Random Allocation 12%
30. Personal Autonomy 12%
31. Intensity-Modulated Radiotherapy 11%
32. Neck Dissection 11%
33. Enteral Nutrition 10%
34. Deglutition 9%
35. Cost-Benefit Analysis 8%
36. Smokers 7%
37. History 7%
38. Smoking 6%
39. Costs and Cost Analysis 5%
40. Child 5%
41. Pharmaceutical Preparations 5%